Not all single inhaler triple therapies are the same.

Trelegy Ellipta is the only triple therapy for COPD to contain Fluticasone Furoate (ICS), Umeclidinium(LAMA) and Vilanterol (LABA) in one device.¹ Three molecules specifically selected for their long duration of action.²⁻⁵ ¹¹

*The clinical significance of this is not known.

Fluticasone furoate and vilanterol are not licensed as monotherapies in COPD.

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta were designed to provide a long duration of action for patients with COPD.²⁻⁵ ¹¹

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/fluticasone-furoate-molecule-design-story.mp4

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta were designed to provide a long duration of action for patients with COPD.²⁻⁵ ¹¹

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/umeclidnium-molecule-design-story.mp4

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta were designed to provide a long duration of action for patients with COPD.²⁻⁵ ¹¹

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/vilanterol-molecule-design-story.mp4

What does this mean for your patients?

Trelegy Ellipta has been intentionally designed to provide your patients with sustained efficacy from today, so they can expect more from their tomorrows.¹⁻³

Footnotes

ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA¹

Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.¹ This is not an exhaustive list. Please consult the Summary of Product Characteristics for a full list of adverse reactions before prescribing.

In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.¹

References:

  1. Trelegy Ellipta SmPC.
  2. Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
  3. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
  4. Lipson DA et al. Poster presented at ATS 2017; Poster 372.
  5. Kempsford R et al. Pulm Pharmacol Ther 2013; 26:256–264.
  6. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  7. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873–1880.
  8. Svedsater H et al. BMC Pulm Med 2013; 13:72–86.
  9. Biggadike K et al. J Med Chem 2008; 51: 3349-3352.
  10. Salter M et al. Am J Physiol Lung Cell Mol Physiol 2007; 293:L660-L667.
  11. Incruse Ellipta (umeclidinium bromide) SmPC.
  12. Laine DI et al. J Med Chem 2009; 52:2493-2505.
  13. Salmon M et al. J of Pharm. & Exp. Ther. 2013; 345:260-270.
  14. Hanania NA;CHEST;2012;142;119-127.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-200017(V 2.0) | September 2020